Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
Eli Lilly and Company
Masonic Cancer Center, University of Minnesota
Altor BioScience
Dartmouth-Hitchcock Medical Center